The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic (PK/PD) of ascending single oral dose of BR-A-657 in healthy male subjects.

BR-A-657 20, 50, 120, 240, 360, 480mg or placebo were administered once to healthy male subjects.

Pharmacokinetic and Pharmacodynamic(PK/PD) parameters were monitored at pre-specified times from each subjects.

PK parameters: Area Under the Curve(AUC), Cmax, half-life, etc. PD parameters: Aldosterone, Plasma renin activity, Angiotensin I, Angiotensin II Adverse events are reported.

Inclusion Criteria:

• male of 18-55 years old
• Body Mass Index(BMI) 19-29kg/m2
• subjects in good health
• subjects with written informed consent

Exclusion Criteria:

• subjects with multiple drug allergy or allergy to Angiotensin Receptor Blocker(ARB)
• subjects with medication that affect drug absorption or elimination within 30days.
• subjects with orthostatic hypotension of >20mmHg decrease of Systolic Blood Pressure(SBP)
• subjects with history of neurologic, liver, renal, gastrointestinal, cardiovascular, psychological or other major disorder